South Korea MFDS Innovative Device Approval: The 240-Day Fast-Track Plan
Medical Device Global Market AccessSummary
South Korea's Ministry of Food and Drug Safety (MFDS) has announced a significant initiative aimed at expediting the approval process for innovative medical devices. The new medical product approval and review innovation plan, effective from October 19, 2026, sets a target of completing reviews within 240 days, presenting a substantial opportunity for manufacturers of novel technologies to bring their products to market more quickly.
The plan introduces three key components to streamline the submission and review process. Firstly, a detailed approval checklist is implemented to clarify the specific data and documentation required for innovative devices, helping to minimize incomplete submissions and delays. Secondly, the establishment of formal pre-submission meetings allows manufacturers to engage directly with MFDS reviewers, facilitating discussions on technology, clinical data, and regulatory strategies before official applications are filed. Lastly, the introduction of a parallel rolling review system enables simultaneous evaluation of different sections of the technical dossier, significantly reducing the overall review timeline.
Manufacturers are encouraged to take proactive steps to leverage these changes, including assessing their product pipeline for eligibility under the new criteria, utilizing the detailed checklist for gap analysis, planning for pre-submission meetings, and adapting internal processes to support the rolling review model. These measures are essential for navigating the new fast-track pathways and optimizing regulatory submissions in the South Korean market.
Show Notes
South Korea's Ministry of Food and Drug Safety (MFDS) has renewed its commitment to the 'Medical Product Approval and Review Innovation Plan,' aiming to approve innovative medical devices within 240 days. This episode details the plan's three core components—a new detailed approval checklist, formal pre-submission meetings, and a parallel, rolling review system—and explores what these changes mean for manufacturers seeking faster market entry into South Korea.
Key Questions: - How can you get your innovative medical device approved in South Korea in just 240 days? - What is the new MFDS detailed approval checklist and how should you use it? - Is a formal pre-submission meeting with the MFDS right for your device? - How does a parallel, rolling review system change your submission strategy? - What criteria does the MFDS use to define an 'innovative' medical device? - What are the common pitfalls that can delay your application despite these new measures? - How can you prepare your technical dossier to align with the new rolling review process?
Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIHm1avh_zR3r__GEputWmnXdRNy6ghG9oIHJznapB2Emmw3H31qqkuGgtPJVO53JearAF4wGj1ADZNtCM8S7d2ZKfK0Jyqd9QzKCosEFztmTaYgPM_bIOAgMAouMxVSNxxTtL3uzPOWUrAD6yySryRwQJV6ZxFiyHFqh5J8OxYz4qM4CEpdbVGMItAIpdbQ== - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQelc0pOvLjSD4zPA5w2jm6zfZQazrzN72JglQrJqqdF1qD3LMIQ-Ie2pCswZyNX_cVtW54Q9sWVoT10w-lPSgIIEfeOVxejngctstUnlOPBVf3uODRyVwT82Qn9jZMEEdmeR5jp8m-pAvnegJduJ-JOrirO3hGWx1-ZJGTsS_
How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies access global markets faster. Our team in South Korea offers local expertise to navigate the MFDS innovative device pathway, from developing a regulatory strategy and preparing technical dossiers to acting as your local representative. We leverage advanced AI tools to streamline documentation and ensure your submission is optimized for the new parallel review system. Whether you're a startup or a multinational, we can help you achieve faster, more predictable market entry. Contact us at [email protected] or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.
More from Medical Device Global Market Access
China's NMPA has released its final Good Manufacturing Practice (GMP) inspection guideline, which becomes mandatory on November 1, 2026. This episode provides a detailed breakdown of the 200 inspection items, with a special focus on the 39 high-risk critical points that can lead to an automatic inspection failure. We outline a clear, actionable strategy for medical device manufacturers, both domestic and foreign, to conduct gap analyses, update their quality systems, and prepare for the stringent new requirements to maintain market access in China.
China's National Medical Products Administration (NMPA) is enforcing a revised Good Manufacturing Practice (GMP) for medical devices starting November 1, 2026. This episode provides a practical guide for quality and regulatory teams on how to prepare for this first major update since 2014. We cover the stricter requirements for lifecycle risk management, supplier controls, and contract manufacturing (entrusted production), and outline the concrete steps manufacturers must take to ensure their quality management systems are compliant by the deadline to avoid enforcement actions.
Indonesia is implementing mandatory Halal certification for Class A medical devices, with a critical deadline of October 18, 2026. This episode breaks down what the Halal Product Assurance Law means for manufacturers of low-risk devices. We cover the scope of affected products, the intricacies of the certification process overseen by the BPJPH, and the comprehensive requirements that extend from raw materials to final distribution. We provide practical, actionable steps for regulatory, quality, and market-access teams to prepare for this significant compliance shift and maintain access to the Indonesian market.
Swissmedic has activated the importer linking function in the swissdamed database as of October 1, 2026. This creates a new mandatory step for Swiss importers, who now have until April 1, 2027, to electronically link their actor registration (CHRN) to the devices they place on the market. This episode breaks down the new obligation, explains its dependency on prior device registration by manufacturers and Swiss Authorized Representatives (CH-REPs), and outlines practical steps for all economic operators to ensure compliance before the deadline.
On October 6, 2026, the European Commission selected the first group of high-risk medical devices to undergo a Joint Clinical Assessment (JCA) under the new EU Health Technology Assessment Regulation (HTAR). This episode explains what this pivotal moment means for medical device manufacturers, which device categories are impacted, and how the JCA will reshape the pathway for pricing, reimbursement, and market access across the European Union. We discuss the heightened evidence requirements and provide practical steps for regulatory and market access teams to prepare for this new centralized assessment system.